about
Modifiable Factors and Genetic Predisposition Associated with Gallbladder Cancer. A Concise ReviewA novel therapeutic effect of statins on nephrogenic diabetes insipidusGallstone disease: Symptoms and diagnosis of gallbladder stonesBovine pericardium patch wrapping intestinal anastomosis improves healing process and prevents leakage in a pig modelCaveolin-1 and mitochondrial alterations in regenerating rat liverSevere liver steatosis correlates with nitrosative and oxidative stress in ratsGenome-wide meta-analyses identify three loci associated with primary biliary cirrhosisLoss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel SyndromeOxidative stress in symptom-free HCV carriers: relation with ALT flare-up.Gastrointestinal symptoms and motility disorders in patients with systemic sclerodermaThe Vibrio cholerae cytolysin promotes chloride secretion from intact human intestinal mucosaEffects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption.Pathogenic role of oxidative and nitrosative stress in primary biliary cirrhosis.Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice.Targets for current pharmacologic therapy in cholesterol gallstone disease.Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin.Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options.Liver glycerol permeability and aquaporin-9 are dysregulated in a murine model of Non-Alcoholic Fatty Liver Disease.Pathways of cholesterol crystallization in model bile and native bile.Measurements of gallbladder motor function by ultrasonography: towards standardization.Water handling and aquaporins in bile formation: recent advances and research trends.Estrogen induces two distinct cholesterol crystallization pathways by activating ERα and GPR30 in female mice.Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.Water transport into bile and role in bile formation.Ion transport across the gallbladder epithelium.Modulation of cholesterol crystallization in bile. Implications for non-surgical treatment of cholesterol gallstone disease.Drugs affecting biliary lipid secretion and gallbladder motility: their potential role in gallstone treatment and prevention.Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice.The deletion of the estrogen receptor α gene reduces susceptibility to estrogen-induced cholesterol cholelithiasis in female miceCholesterol gallstone disease.Current pharmacological treatment of nonalcoholic fatty liver.Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts.Current views on genetics and epigenetics of cholesterol gallstone diseaseA silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.Non-alcoholic fatty liver disease in the metabolic syndrome.Targeting the liver in the metabolic syndrome: evidence from animal models.Current treatments of primary sclerosing cholangitis.Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis.Molecular pathophysiology and physical chemistry of cholesterol gallstones.
P50
Q26781145-6F4782A4-962E-4568-9E06-134C8FFA2718Q27005638-18D096E9-7F13-411E-9DF7-3AE98D0E1657Q28275624-57FC6C68-767A-4A46-BED0-A27F760F9063Q28539283-BDAB2797-952C-4A8C-B8F9-45DC92AD70D1Q28576372-C6DAF28A-9F04-43B1-AC59-4E6A2096B51BQ28576818-FBE55402-CFF7-4F3B-9232-DFAAB9DA63BDQ28943317-12DAE777-5E04-4C79-9134-7156F88DD74FQ29544671-D232F0ED-8E72-442B-922F-FA8AEB87C642Q31898205-7F553006-B441-4D78-AACF-4BF3D96D3B6CQ33321445-64DC6E6D-37B5-49D4-A2E8-AA914CDF4E6DQ33424509-ACE09522-DE31-4DC5-957A-2FF094B0B713Q33464876-B9867F0A-5793-474F-A593-1F94BC2D4086Q33626823-8C1C7107-D734-4D16-978B-4713E645AC03Q33698042-CA0C486F-5AE5-4D39-B73A-EE0FFFC8A617Q34041538-D02A8562-4229-4B25-A1D5-64A8CAAE2C22Q34694675-75E2ECF5-FB7C-40EC-A31F-E69E04C2398CQ34960559-58541D2A-F25B-4B73-BFEF-6FB7B911F561Q35036094-EEA6FCC8-8969-406D-9FEF-990301D2CC0DQ35127807-254E7915-1364-450C-8565-1570F466ACF9Q35219119-9AEB7666-8935-4834-88EA-2B893F3615BBQ35563924-B49545F2-F804-4BC0-B123-A80B2AE10D41Q35994356-2A6BEBE1-9FEE-4089-A395-CC18AA641763Q36039854-C4CF087F-F07D-4F5A-AFAD-3AD599E2AF00Q36223420-32CE5393-B3C4-47D7-A684-658677D4153EQ36223425-A98475F9-46B5-408F-88D2-589B76EAC6FDQ36223448-10AE0952-E58B-4354-8B1C-5C71C05EB69AQ36223452-09061E41-983E-4831-AB50-EC6F3EC120C7Q36319448-45746711-3A09-4921-92F8-1F6320CBED95Q36429659-3DCB06B7-A92E-42B4-8234-739D0EA8FB6FQ36537711-61E4D5E6-C503-4D06-88B1-D0EE2DBFA942Q36638628-D17413C7-80D3-4C97-A948-3BA8BFE6D099Q36683930-BA6E6C28-44C0-4F06-9578-88987DFAAF9FQ36744903-D6E2D4F2-3DF3-410F-89E7-31788D6DFE02Q36829866-D8F41916-E1DF-4A73-A20E-0F75A8D1B839Q36871971-65BCA525-DC0A-4BB4-8E08-C9C6CBD7D750Q36879419-C4EDF665-CCA0-4C86-9B5F-4812E0E79868Q36879424-95C46967-0301-4677-AEA9-F15D19161FC0Q36907309-413F9EA1-C74A-41CB-BF0C-260A59B60859Q36940271-6335F47C-FC82-44E4-884B-64BCB1131787Q36991813-D2652B5B-FFB9-4F41-8830-4FD697188880
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Piero Portincasa
@ast
Piero Portincasa
@en
Piero Portincasa
@es
Piero Portincasa
@nl
Piero Portincasa
@sl
type
label
Piero Portincasa
@ast
Piero Portincasa
@en
Piero Portincasa
@es
Piero Portincasa
@nl
Piero Portincasa
@sl
prefLabel
Piero Portincasa
@ast
Piero Portincasa
@en
Piero Portincasa
@es
Piero Portincasa
@nl
Piero Portincasa
@sl
P106
P1153
7007157491
P21
P31
P496
0000-0001-5359-1471